A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 29, 2015

Primary Completion Date

July 5, 2016

Study Completion Date

July 5, 2016

Conditions

Acute Bacterial Skin and Skin Structure Infection

Interventions

DRUG

Oritavancin

Administered intravenously

DRUG

Warfarin

Administered as a concomitant medication at a standard dose and dosing schedule

Trial Locations (1)

Somers Point